Premium
Healthcare-focussed private equity (PE) firm InvAscent has exited Synergia Life Sciences Pvt Ltd, with over 11-fold returns after the vitamins manufacturer was sold to Denmark-based Novozymes earlier this month. InvAscent, via its second fund, India Life Sciences Fund II, had invested around $6 million in Synergia in 2015 for around ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
